JP2012532200A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532200A5
JP2012532200A5 JP2012519672A JP2012519672A JP2012532200A5 JP 2012532200 A5 JP2012532200 A5 JP 2012532200A5 JP 2012519672 A JP2012519672 A JP 2012519672A JP 2012519672 A JP2012519672 A JP 2012519672A JP 2012532200 A5 JP2012532200 A5 JP 2012532200A5
Authority
JP
Japan
Prior art keywords
antigen
vesicle
lipid
molten
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012519672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532200A (ja
JP5854559B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/041078 external-priority patent/WO2011005769A1/en
Publication of JP2012532200A publication Critical patent/JP2012532200A/ja
Publication of JP2012532200A5 publication Critical patent/JP2012532200A5/ja
Application granted granted Critical
Publication of JP5854559B2 publication Critical patent/JP5854559B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012519672A 2009-07-06 2010-07-06 小胞を調製する方法及びこれから製造される製剤 Expired - Fee Related JP5854559B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22319609P 2009-07-06 2009-07-06
US61/223,196 2009-07-06
US25691209P 2009-10-30 2009-10-30
US61/256,912 2009-10-30
PCT/US2010/041078 WO2011005769A1 (en) 2009-07-06 2010-07-06 Methods for preparing vesicles and formulations produced therefrom

Publications (3)

Publication Number Publication Date
JP2012532200A JP2012532200A (ja) 2012-12-13
JP2012532200A5 true JP2012532200A5 (https=) 2013-08-22
JP5854559B2 JP5854559B2 (ja) 2016-02-09

Family

ID=43429505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519672A Expired - Fee Related JP5854559B2 (ja) 2009-07-06 2010-07-06 小胞を調製する方法及びこれから製造される製剤

Country Status (11)

Country Link
US (1) US9849173B2 (https=)
EP (1) EP2451950B9 (https=)
JP (1) JP5854559B2 (https=)
CN (2) CN107029229B (https=)
AU (1) AU2010270722B2 (https=)
BR (1) BR112012000826B1 (https=)
CA (1) CA2767392C (https=)
ES (1) ES2573427T3 (https=)
IL (2) IL217375A (https=)
MX (1) MX2012000372A (https=)
WO (1) WO2011005769A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL268980B (en) 2009-06-25 2022-09-01 Revance Therapeutics Inc Albumin-free botulinum toxin formulations
JP5854559B2 (ja) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20140328876A1 (en) * 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (en) * 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS
JP5650780B2 (ja) * 2012-04-04 2015-01-07 日東電工株式会社 ワクチン組成物
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) * 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
WO2015079952A1 (ja) * 2013-11-29 2015-06-04 テルモ株式会社 アジュバント組成物およびこれを含むワクチン組成物、並びにこれらの製造方法
CN107405395A (zh) * 2015-03-17 2017-11-28 红杉科学有限公司 疫苗与佐剂的组合物以及治疗尿路感染的方法
WO2016194685A1 (ja) * 2015-06-02 2016-12-08 テルモ株式会社 アルミニウムを含有するアジュバント組成物およびこれを含むワクチン組成物
GB201612108D0 (en) * 2016-07-12 2016-08-24 Univ Strathclyde Preperation of non-ionic surfactant vesicles and variants
GB201814959D0 (en) * 2018-09-14 2018-10-31 Secr Defence Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses
CN116211827B (zh) * 2023-03-17 2024-04-05 浙江大学 一种特立帕肽固体脂质纳米粒及其制备方法和应用
EP4701625A2 (en) * 2023-04-26 2026-03-04 Vivtex Corporation Formulation of therapeutic agents for improved permeation

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024241A (en) 1974-09-27 1977-05-17 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US3952097A (en) 1974-09-27 1976-04-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4349538A (en) 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
JPS56115727A (en) * 1980-02-19 1981-09-11 Kuraray Co Ltd Carrier for immobilizing physiologically active substance
US4537769A (en) 1982-04-06 1985-08-27 American Cyanamid Company Stabilization of influenza virus vaccine
US4894228A (en) 1982-04-07 1990-01-16 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4983387A (en) 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
AU603659B2 (en) 1987-03-13 1990-11-22 Micro Vesicular Systems, Inc. Lipid vesicles formed of surfactants and steroids
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5160669A (en) 1988-03-03 1992-11-03 Micro Vesicular Systems, Inc. Method of making oil filled paucilamellar lipid vesicles
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4911517A (en) 1988-09-09 1990-03-27 Square D Company Means for clamping fiber optical cable
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5817318A (en) 1989-05-03 1998-10-06 Connaught Laboratories Limited Synthetic peptides for an HIV-1 vaccine
CN1022331C (zh) 1989-08-17 1993-10-06 浙江省医学科学院 甲型肝炎减毒活疫苗毒种及其制造方法
DE3934366A1 (de) 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
IT1238343B (it) 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
IE904098A1 (en) 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
BR9106604A (pt) 1990-06-29 1993-06-22 Chiron Corp Composicao de vacina e processo para estimular uma resposta imunologica em um animal hospedeiro
US5250236A (en) 1991-08-05 1993-10-05 Gasco Maria R Method for producing solid lipid microspheres having a narrow size distribution
GB9207731D0 (en) 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
CA2139757C (en) 1992-07-08 2009-04-14 Gunther Maierhofer Liposomes, method of preparing the same and use thereof in the preparation of drugs
EP0666751B1 (en) 1992-09-18 2001-09-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Mutants of hepatitis a virus strain hm-175 for use as hepatitis a vaccines
US5393527A (en) 1993-01-04 1995-02-28 Becton, Dickinson And Company Stabilized microspheres and methods of preparation
ES2145132T3 (es) 1993-02-26 2000-07-01 Fountain Pharm Inc Sistema de suministro de vacunas y solucion precursora estable en almacenamiento para la encapsulacion a distancia de ingredientes activos.
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
CA2163860A1 (en) 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
PL181241B1 (pl) 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JPH09511381A (ja) 1994-01-11 1997-11-18 ブラームス・インターユニバージテーア・インスティテュート・ボーア・ビーオテクノロジー インフルエンザワクチン
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
US20030104576A1 (en) 1994-10-07 2003-06-05 Jonathan W. Nyce Dna construct, composition, formulations & methods for making the construct & for modulating expression
GB9515868D0 (en) 1995-08-02 1995-10-04 Proteus Molecular Design Therapeutic method
GB9522351D0 (en) 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
US5700679A (en) 1996-06-07 1997-12-23 Novavax, Inc. Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity
US5919480A (en) 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
ATE298578T1 (de) 1996-07-03 2005-07-15 Eisai Co Ltd Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung
ZA975889B (en) 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
CN1138533C (zh) 1996-09-13 2004-02-18 利普森有限公司 脂质体
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US6290967B1 (en) 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
FR2760367B1 (fr) 1997-03-06 1999-04-30 Pasteur Merieux Serums Vacc Composition vaccinale destinee a la prevention ou au traitement des hepatites c
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
DE69828507T2 (de) 1997-05-20 2006-01-05 Galenica Pharmaceuticals, Inc. Triterpene-saponin analoga mit adjuvans und immunostimulierender wirkung
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US6503753B1 (en) 1998-02-13 2003-01-07 Adan Rios Method for the development of an HIV vaccine
EP1056838B1 (en) 1998-02-13 2007-06-20 Adan Rios Method for the development of an hiv vaccine
WO1999058726A1 (en) 1998-05-12 1999-11-18 Genecure Llc Replication defective hiv vaccine
US7067134B1 (en) 1998-08-12 2006-06-27 University Of Western Ontario HIV vaccine
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
GB9822714D0 (en) 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
CN1062770C (zh) 1998-11-12 2001-03-07 卫生部长春生物制品研究所 甲肝-麻疹二联疫苗及其生产方法
US6287570B1 (en) 1998-11-23 2001-09-11 Patricia L. Foley Vaccine against swine influenza virus
GB9826069D0 (en) 1998-11-28 1999-01-20 Univ Leeds HIV vaccine
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
CA2378539A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
AU5905400A (en) * 1999-07-14 2001-02-05 Board Of Regents, The University Of Texas System Methods and compositions for delivery and retention of active agents to lymph nodes
BR0012624B1 (pt) 1999-07-15 2011-08-09 métodos para a preparação de agentes terapêuticos envolvidos por lipìdeos.
WO2001007637A2 (en) 1999-07-28 2001-02-01 Stephen Smith Conditionally controlled, attenuated hiv vaccine
PL355287A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
CA2400468C (en) 2000-02-15 2012-12-18 Intellivax International Inc. Proteosome influenza vaccine
FR2806912B1 (fr) 2000-04-04 2004-07-23 Fond Mondiale Rech Et Preventi UTILISATION DE PROTEINES gp120 ET gp160 MODIFIEES DANS LA BOUCLE V3 DU VIH-1 POUR LA PREPARATION DE COMPOSITIONS VACCINALES ET FORMULATIONS LES CONTENANT
US20030092145A1 (en) 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
JP5063852B2 (ja) 2000-09-25 2012-10-31 ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング 生ワクチン及び製造方法
DE60130791T2 (de) * 2000-12-27 2008-07-17 Ares Trading S.A. Amphiphile lipid-nanopartikel zur peptid- und/oder proteininkorporation
GB0111279D0 (en) * 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
WO2003059385A2 (en) 2002-01-14 2003-07-24 Chiron Corporation Hiv vaccine and method of use
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
US20050169979A1 (en) 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
US7604803B2 (en) 2002-07-05 2009-10-20 Lipoxen Technologies Limited Method to enhance an immune response of nucleic acid vaccination
US20040011840A1 (en) 2002-07-22 2004-01-22 Lovett Terry E. Rolling motorcycle bag
EP2481819A1 (en) 2003-02-25 2012-08-01 MedImmune Vaccines, Inc. Cross flow filtration in the production of stabilized influenza vaccine compositions
ES2529736T3 (es) 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
MXPA05012199A (es) 2003-05-15 2006-02-10 Univ Oklahoma State Vacuna de dna que expresa ha1 del virus de influenza equina-2.
EP1638919B1 (en) 2003-06-18 2012-09-26 Biolab Ltd. Sphingolipids polyalkylamines conjugates
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US20050095283A1 (en) 2003-09-16 2005-05-05 Aphios Corporation Compositions and methods for topically treating diseases
US20080160089A1 (en) 2003-10-14 2008-07-03 Medivas, Llc Vaccine delivery compositions and methods of use
WO2005053727A2 (en) * 2003-11-29 2005-06-16 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
JP4980895B2 (ja) 2004-05-25 2012-07-18 メディミューン，エルエルシー インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体
EP2269638A3 (en) 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
JP4987704B2 (ja) * 2004-07-07 2012-07-25 スタテンス セールム インスティトゥート 糖脂質を用いた、脂質系アジュバント製剤を安定化する組成物及び方法
CA2582242A1 (en) * 2004-10-08 2006-04-20 Alza Corporation Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
US7510719B2 (en) 2004-12-08 2009-03-31 Medimmune, Llc Methods of producing influenza vaccine compositions
EP1676569A1 (en) 2004-12-30 2006-07-05 Pevion Biotech Ltd. Lyophilization of virosomes
US8029797B2 (en) 2005-03-01 2011-10-04 Variation Biotechnologies Inc. Multivalent HIV immunogenic compositions comprising a pool of lipidated and nonlipidated peptides representing Gag and Env variable regions
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20090028903A1 (en) 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
US7348011B2 (en) 2005-06-10 2008-03-25 Sudershan Biotech Ltd. Hepatitis C virus vaccine
WO2006138719A2 (en) 2005-06-17 2006-12-28 Georgia Tech Research Corporation Coated microstructures and method of manufacture thereof
JP4538522B2 (ja) 2005-11-25 2010-09-08 コーリー ファーマシューティカル ゲーエムベーハー 免疫刺激性オリゴリボヌクレオチド
EP2441846A3 (en) 2006-01-09 2012-07-25 The Regents Of the University of California Immunostimulatory combinations of TNFRSF, TLR, NLR, RHR, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy
EP1988918A4 (en) 2006-02-22 2010-04-28 Novavax Inc ADJUVANZ AND VACCINE COMPOSITIONS
US8846078B2 (en) * 2006-03-21 2014-09-30 The Secretary Of State For Environment, Food & Rural Affairs Acting Through The Animal Health And Veterinary Laboratories Agency Brucellosis DNA vaccine
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
JP5072275B2 (ja) * 2006-07-03 2012-11-14 テルモ株式会社 閉鎖小胞の分離方法、製剤の製造方法および評価方法
WO2008082721A2 (en) 2006-09-05 2008-07-10 Medivas, Llc Polymer-stabilized liposomal compositions and methods of use
PL2068918T5 (pl) * 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CA2680060A1 (en) 2007-03-07 2008-09-12 Nventa Biopharmaceuticals Corporation Double-stranded locked nucleic acid compositions
US11246831B2 (en) 2007-03-30 2022-02-15 Particle Sciences, Inc. Particle formulations and uses thereof
WO2008153236A1 (en) 2007-06-15 2008-12-18 Protheon Co., Ltd An attenuated influenza virus and a live vaccine comprising the same
EP2014279A1 (en) 2007-06-22 2009-01-14 Pevion Biotech AG Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
EP2192917B1 (en) 2007-08-28 2014-01-29 Baxter International Inc. Method for producing viral vaccines
WO2009091531A2 (en) 2008-01-16 2009-07-23 The General Hospital Corporation Uniform-sized, multi-drug carrying and photosensitive liposomes for advance drug delivery
CN101574394A (zh) 2008-05-09 2009-11-11 北京因科瑞斯医药科技有限公司 马钱子生物碱囊泡及其制备方法
CA2735724C (en) 2008-06-19 2018-07-24 Variation Biotechnologies Inc. Compositions and methods for treating influenza
WO2010033812A1 (en) * 2008-09-18 2010-03-25 Variation Biotechnologies, Inc. Compositions and methods for treating hepatitis a.
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
JP5854559B2 (ja) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
WO2012006368A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
BR112013018074A2 (pt) 2011-01-13 2020-12-01 Variation Biotechnologies, Inc. métodos para a preparação de vesículas e formulações produzidas a partir dessas
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS

Similar Documents

Publication Publication Date Title
JP2012532200A5 (https=)
Van Braeckel-Budimir et al. Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications
US20240002127A1 (en) Coronavirus vaccine
JP6119030B2 (ja) インフルエンザを治療するための組成物及び方法
MX2012000372A (es) Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
JP2010505785A5 (https=)
Nguyen et al. Skin immunization with third-generation hepatitis B surface antigen using microneedles
JP2013533259A5 (https=)
CA2922959A1 (en) Orally administrable composition
CN103533923A (zh) 囊泡及由其产生之制剂的制备方法
US11304999B2 (en) Dried composition of saponin in a liposomal formulation with a neutral lipid, a sterol, and a cryoprotectant
RU2014133089A (ru) Способы и композиции для терапевтических агентов
CN103501811B (zh) 用于治疗病毒感染的组合物和方法
CN110035770A (zh) 新方法
EP4687853A1 (en) Lipid nanoparticle compositions
Porte et al. A molecular view of lipid nanoparticles: insights into their morphology and structural plasticity
Nielsen et al. ISCOMs as a vaccine delivery system
WO2012006368A2 (en) Compositions and methods for treating influenza
JP2018503629A5 (https=)
Kabarkouhi et al. Liposome, nanoliposome and allied technologies in COVID-19 vaccines: key roles and functionalities
US10973900B2 (en) Dried composition
Samiei et al. Engraftment of plasma membrane vesicles into liposomes: A new method for designing of liposome-based vaccines
Wilkhu Non-ionic surfactant technology for the delivery and administration of sub-unit flu antigens
Khan et al. mRNA vaccines: Immunology and present and future potential
US20160199480A1 (en) Method for preparing virosomes